bpc-157 clinical trials human evidence review safety regulatory status BPC-157 BPC-157 | Reviews, Clinical Trials,
Description
The highest dose studied in Phase 2, producing up to 24.2% average weight loss at 48 weeks
In exon 14-mutated NSCLC, secondary mutations have been identified in the kinase domain that are associated with resistance to c-MET inhibitors
GH stimulates collagen synthesis, and some researchers report improved skin texture, hydration, and elasticity during this phase
In addition, DPP-4 modulates multiple substrates such as GLP-1, BNP, substance P, and neuropeptide Y (NPY), leading to potential extra-pancreatic effects, particularly the promotion of sodium excretion in urine (186)
